Affymetrix’s announcement last week that it plans to acquire Panomics for $73 million in cash did not go unnoticed by Panomics’ customers, several of whom this week said they were surprised by the move and expressed concern about how the deal may impact their ongoing research programs.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.